YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Investing.com -- H Lundbeck (LON:0ND5) has expressed interest in a potential takeover of Chicago-based commercial-stage drugmaker Xeris Pharmaceuticals Inc (NASDAQ:XERS), according to people familiar with the matter cited by Bloomberg. The…
H. Lundbeck (CPSE:HLUN B) has just secured Japanese marketing authorization for eptinezumab in migraine prevention, a fresh regulatory milestone that broadens its neuroscience footprint and adds another data point for investors watching th…
This article first appeared on GuruFocus. Revenue: DKK 13.6 billion, up 16% at constant exchange rates, with underlying growth of around 13%. Adjusted Gross Margin: 86.7%, reflecting commission costs from the partnership model and unfavora…
[Profile of Male Head with Brain Stem Anatomy Labeled] Hank Grebe/iStock via Getty Images Lundbeck (HLBBF [https://seekingalpha.com/symbol/HLBBF])(HLUBF [https://seekingalpha.com/symbol/HLUBF])(HLBBY [https://seekingalpha.com/symbol/HLBBY]…
This article first appeared on GuruFocus. Revenue: DKK7.1 billion, growing 21%, with an underlying growth of 13% at constant exchange rates. Vyepti Revenue: DKK1.364 billion in Q1 2026, growing 47% at constant exchange rates. Rexulti Reven…
This article first appeared on GuruFocus. Revenue: DKK 24.6 billion, growing 13% at constant exchange rates. Strategic Brands Growth: 19% growth, driven by Rexulti and Vyepti. Adjusted Gross Margin: 87.5%. Sales and Distribution Costs: Dec…
[M&A Mergers And Acquisitions] narvo vexar Alkermes (ALKS [https://seekingalpha.com/symbol/ALKS]) has raised its buyout offer for Avadel Pharmaceuticals (AVDL [https://seekingalpha.com/symbol/AVDL]), indicating a price of up to $22.50 per…
This article first appeared on GuruFocus. VYEPTI Global Net Revenue: DKK3.254 billion, 57% growth year-over-year. VYEPTI US Net Revenue: DKK2.8 billion, 56% growth year-over-year. REXULTI Revenue: DKK4.695 billion, 26% growth year-over-yea…
Trying to decide whether to jump into H. Lundbeck stock right now? You are not alone. With the share price closing at 44.92 and making strong upward moves of 3.9% this past week and 12.6% over the past month, plenty of investors are watchi…
Company Logo The United States Epilepsy Drugs Market is projected to grow from US$ 2.36 billion in 2024 to US$ 3.45 billion by 2033, marking a CAGR of 4.31% from 2025 to 2033. This growth is fueled by the rising prevalence of epilepsy, aff…
Company Logo Denmark's pharmaceutical market is projected to grow from US$ 3.81 billion in 2024 to US$ 5.20 billion by 2033, with a CAGR of 3.52%. Key drivers include advanced health data infrastructure, supportive government policies, hea…
No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic alpha-synuclein while preserving normal function is vit…
Company Logo The Global Bipolar Disorder Market report forecasts significant growth from 2025 to 2035, driven by rising prevalence, awareness, and pharmacotherapy advancements. Bipolar disorder, marked by severe mood swings, impacts millio…
[A pill bottle with a head on it and the words Post Traumatic Stress Disorder written below it] Inna Kot/iStock via Getty Images The FDA staffers on Wednesday cited efficacy issues related to a combination regimen involving brexpiprazole,…
Company Logo The global alcohol use disorder market is experiencing significant growth, driven by increasing demand for innovative and personalized treatments, and the integration of digital health technologies. Advancements in pharmacothe…
Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2 A phase II trial has recently been initiated to investigate the efficacy and sa…
The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically significant reductions in mean monthly migraine days (MMD…
Brexpiprazole's indication for the treatment of schizophrenia in adults is extended to include adolescents aged 13 years and older1 Approval follows a positive Committee for Medicinal Products for Human Use (CHMP) opinion from the European…